AGTX (Agentix) Retained Earnings : $-6.34 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Agentix Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Agentix's retained earnings for the quarter that ended in Dec. 2024 was $-6.34 Mil.

Agentix's quarterly retained earnings declined from Jun. 2024 ($-6.11 Mil) to Sep. 2024 ($-6.20 Mil) and declined from Sep. 2024 ($-6.20 Mil) to Dec. 2024 ($-6.34 Mil).

Agentix's annual retained earnings declined from Aug. 2021 ($-1.70 Mil) to Mar. 2023 ($-5.37 Mil) and declined from Mar. 2023 ($-5.37 Mil) to Mar. 2024 ($-5.95 Mil).

Agentix Retained Earnings Historical Data

The historical data trend for Agentix's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Retained Earnings Chart

Agentix Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Mar23

Mar24

Retained Earnings

Get a 7-Day Free Trial

-44.03

-0.36

-1.70

-5.37

-5.95

Agentix Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-5.95	-5.95	-6.11	-6.20	-6.34

Agentix Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Agentix (OTCPK:AGTX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Agentix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629

Website

https://www.agentixcorp.com

Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.

Executives

Thomas E Puzzo	10 percent owner	4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter	director, 10 percent owner, officer: President, CEO, CFO, Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc	10 percent owner	320 PARK AVE, NEW YORK NY 10022
Scott B Stevens	director, officer: President and Director	9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen	director, officer: Secretary and Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius	director, 10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han	10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix Headlines

No Headlines